Key Highlights

  • Third-quarter 2026 net loss was USD 78.1 million, against USD 56.9 million.
  • Collaboration and license Revenue was USD 4.1 million, against USD 0.1 million.
  • Research and development expenses were USD 69.8 million, up 41% year over year.
  • Nine-month net loss was USD 219.8 million, against USD 159.5 million.

4D Molecular Therapeutics (NASDAQ:FDMT) reported third-quarter 2026 loss per share of USD 1.08, against an estimate of USD 1.05. Revenue was USD 4.14 million, against an estimate of USD 4.13 million. The company develops gene therapy product candidates, including 4D-150, 4D-175, 4D-710 and 4D-725.

The filing states net losses of USD 78.1 million and USD 56.9 million for the three months ended September 30, 2026 and 2025, and USD 219.8 million and USD 159.5 million for the nine months.

Revenue and Expenses

Collaboration and license revenue was USD 4,145 thousand for the quarter, against USD 90 thousand, and USD 10,974 thousand for the nine months, against USD 119 thousand. Revenue from Otsuka Pharmaceutical was USD 4,055 thousand for the quarter and USD 10,704 thousand for the nine months, and revenue from the Cystic Fibrosis Foundation was USD 90 thousand for the quarter.

Research and development expenses were USD 69,776 thousand, against USD 49,438 thousand, and USD 203,038 thousand for the nine months, against USD 138,088 thousand, an increase of 47%. The filing says Research and Development expenses increased by USD 20.3 million, or 41%, for the quarter, primarily due to the progression of clinical and Manufacturing activities for wet AMD and DME.

General and administrative expenses were USD 15,587 thousand, against USD 11,837 thousand, an increase of USD 3.8 million, or 32%, and USD 39,798 thousand for the nine months, an increase of 10%. Total operating expenses were USD 85,363 thousand, against USD 61,275 thousand, and the loss from operations was USD 81,218 thousand, against USD 61,185 thousand. Other income, net, decreased USD 1.1 million, or 27%, for the quarter.

Cash, Securities and Financing

At September 30, 2026, cash and cash equivalents were USD 39,104 thousand, against USD 60,241 thousand at December 31, 2025. Marketable securities were USD 267,885 thousand, with long-term marketable securities of USD 68,044 thousand, for total cash and marketable securities of approximately USD 375.0 million. The nine-month net decrease in cash and cash equivalents was USD 21,137 thousand, and financing activities provided USD 54,427 thousand, against USD 978 thousand.

The filing describes a November 2025 underwritten offering in which 8,385,809 shares were sold at USD 10.51 per share, along with pre-funded warrants to purchase 1,128,949 shares at USD 10.5099 per underlying share. It also describes a Loan Facility with an initial borrowing of USD 20.0 million at a floating rate equal to the greater of the prime rate plus 2.0% and 8.75%, with an available balance of USD 30.0 million of a USD 50.0 million Tranche as of June 24, 2026 at a floating rate equal to the greater of the prime rate plus 2.5% and 9.25%.

Balance Sheet Items

A collaboration receivable of USD 4,021 thousand was outstanding at September 30, 2026. Total current Assets were USD 322,286 thousand, property and equipment, net, was USD 11,224 thousand and operating Lease right-of-use assets, net, were USD 15,758 thousand. Accrued and other current liabilities were USD 35,211 thousand, against USD 26,874 thousand. The total value of non-cancellable obligations under contracts was USD 4.3 million, against USD 4.0 million at December 31, 2025.